A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

Financial Distress Screening and Financial Navigation Among Adolescents and Young Adults Within the National Cancer Institute Community Oncology Research Program: Results of the 2022 Landscape Survey ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...